Linked Life Data

3957502

Source:http://linkedlifedata.com/resource/pubmed/id/3957502

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-5-7
pubmed:abstractText
In this double-blind study versus placebo, the anti-migraine efficacy of flunarizine 20 mg/per os/day for 14 days, followed by 10 mg/per os/day up to 120 days has been evaluated in 30 patients suffering from common and classical migraine. During the trial the vestibular function (slow phase velocity (SPV) and number of spikes) was also studied. To date 18 patients have completed the study. The results show a significant difference before and after the treatment with flunarizine, while no difference was observed in the placebo group, with regard to headache unit indices. Flunarizine seems to increase SPV max, which is reduced between attacks in migraine patients; the number of spikes does not change significantly.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0251-1649
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-32
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Effectiveness of flunarizine in altering electronystagmographic patterns in migraine patients: a preliminary report.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't